Painreform Ltd
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinica… Read more
Painreform Ltd (PRFX) - Net Assets
Latest net assets as of September 2025: $8.44 Million USD
Based on the latest financial reports, Painreform Ltd (PRFX) has net assets worth $8.44 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.16 Million) and total liabilities ($2.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.44 Million |
| % of Total Assets | 75.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | -89.03% |
| 10-Year Change | N/A |
| Growth Volatility | 29.66 |
Painreform Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Painreform Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Painreform Ltd (2017–2024)
The table below shows the annual net assets of Painreform Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.82 Million | -74.80% |
| 2023-12-31 | $7.24 Million | -34.32% |
| 2022-12-31 | $11.02 Million | -39.05% |
| 2021-12-31 | $18.08 Million | +8.80% |
| 2020-12-31 | $16.62 Million | +395.62% |
| 2019-12-31 | $-5.62 Million | -26.14% |
| 2018-12-31 | $-4.46 Million | -22.82% |
| 2017-12-31 | $-3.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Painreform Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4613000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $58.27 Million | 3194.90% |
| Total Equity | $1.82 Million | 100.00% |
Painreform Ltd Competitors by Market Cap
The table below lists competitors of Painreform Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zelira Therapeutics Limited
OTCQB:ZLDAF
|
$1.87 Million |
|
Archies Limited
NSE:ARCHIES
|
$1.87 Million |
|
Rich Goldman Holdings Limited
F:MRU3
|
$1.87 Million |
|
SQX Resources Ltd
AU:SQX
|
$1.87 Million |
|
TinOne Resources Inc.
OTCQB:TORCF
|
$1.87 Million |
|
Mistral Patrimonio Inmobiliario SOCIMI SA
MC:YMPI
|
$1.87 Million |
|
T-MOBILE US (TM5.SG)
STU:TM5
|
$1.87 Million |
|
Triboron International AB (publ)
ST:TRIBO-B
|
$1.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Painreform Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,239,000 to 1,824,000, a change of -5,415,000 (-74.8%).
- Net loss of 14,588,000 reduced equity.
- New share issuances of 5,350,000 increased equity.
- Other factors increased equity by 3,823,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.59 Million | -799.78% |
| Share Issuances | $5.35 Million | +293.31% |
| Other Changes | $3.82 Million | +209.59% |
| Total Change | $- | -74.80% |
Book Value vs Market Value Analysis
This analysis compares Painreform Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1573.72 | $2.42 | x |
| 2018-12-31 | $-1932.78 | $2.42 | x |
| 2019-12-31 | $-3624.76 | $2.42 | x |
| 2020-12-31 | $8514.34 | $2.42 | x |
| 2021-12-31 | $11059.33 | $2.42 | x |
| 2022-12-31 | $6202.03 | $2.42 | x |
| 2023-12-31 | $3317.60 | $2.42 | x |
| 2024-12-31 | $100.54 | $2.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Painreform Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -799.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.48x
- Recent ROE (-799.78%) is below the historical average (-134.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.73 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-382.30K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.26 Million |
| 2020 | -24.39% | 0.00% | 0.00x | 1.07x | $-5.71 Million |
| 2021 | -40.07% | 0.00% | 0.00x | 1.05x | $-9.05 Million |
| 2022 | -79.77% | -10223.26% | 0.01x | 1.12x | $-9.89 Million |
| 2023 | -129.08% | 0.00% | 0.00x | 1.37x | $-10.07 Million |
| 2024 | -799.78% | 0.00% | 0.00x | 2.48x | $-14.77 Million |
Industry Comparison
This section compares Painreform Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Painreform Ltd (PRFX) | $8.44 Million | 0.00% | 0.32x | $1.87 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |